Why take this course?
A positive sterility result immediately raises a difficult question: did contamination occur during laboratory testing, or does the result indicate a genuine product or manufacturing failure? Answering that requires more than reviewing the test itself. Investigators must examine laboratory controls and practices, manufacturing and filling conditions, environmental data, personnel, equipment, utilities, materials, process history, and other evidence that could explain the contamination.
The investigation becomes more difficult when several plausible causes exist or the evidence does not establish one definitive source. This session examines how to move from possible causes to an evidence-supported conclusion, including contamination-source evaluation, root cause analysis, investigation scope, affected-batch assessment, documentation, and CAPA. It also addresses when evidence may support invalidating a sterility result and when inconclusive findings cannot justify that conclusion.
Key Areas Covered
Danielle DeLucy
Danielle DeLucy, has 25 years of pharmaceutical and biologics industry experience across Quality Management, Product Quality, Sterility Assurance, and QA oversight of filling and packaging operations. Her background as a Quality Control Pharmaceutical Microbiologist, combined with experience leading regulatory health inspections, directly supports the aseptic processing, contamination control, and media fill considerations addressed in this webinar.
Commonly Asked Questions About This Subject
How much evidence is needed before a sterility test failure can reasonably be attributed to laboratory error?
A laboratory cause needs positive evidence. Finding a possible weakness in aseptic technique, equipment handling, or test execution does not demonstrate that the weakness actually caused the sterility failure.
This distinction becomes critical when invalidating a sterility test. Investigators should be able to connect the proposed laboratory event to the contamination observed through organism identification, test chronology, environmental or personnel monitoring, equipment records, procedural observations, or other relevant evidence. A hypothetical route of contamination provides a lead for investigation, but it is a weak basis for excluding the original result.
Inspection friction develops when the investigation appears to search for any plausible laboratory explanation that permits retesting. Statements such as "possible analyst contamination" become especially vulnerable when the manufacturing investigation was limited because the laboratory explanation was accepted early.
When evidence remains inconclusive, the record should preserve that uncertainty. An unsupported definitive root cause creates greater regulatory exposure than a scientifically honest investigation that acknowledges what could and could not be established.
What should investigators do when the microorganism found in a sterility failure does not match organisms recovered from environmental monitoring?
The mismatch should broaden the investigation rather than automatically clear the manufacturing environment. Environmental monitoring provides important evidence, but it samples selected locations and times and cannot demonstrate the absence of a contamination source throughout the entire process.
The organism should be evaluated against potential sources across laboratory testing, personnel, raw materials, utilities, equipment, components, interventions, cleaning and disinfection, and the manufacturing environment. Identification to an appropriate level can materially strengthen or weaken competing hypotheses.
A frequent weakness is treating "no matching environmental isolate" as evidence that contamination must have occurred during laboratory testing. That conclusion requires its own supporting evidence.
The useful question is whether the organism's characteristics and the event chronology fit a credible contamination pathway. Investigators should also consider whether historical isolates or related organisms have appeared previously. Microbiological identification carries weight when it helps discriminate among competing explanations, rather than being used selectively to support the most convenient one.
How should a sterility failure be investigated when no single assignable root cause can be established?
The investigation should document the strongest supported hypotheses, eliminate explanations where evidence permits, and assess product impact without manufacturing certainty that the evidence cannot support. An inconclusive investigation can still be scientifically rigorous.
Sterility failures are particularly difficult because contamination events may be transient and leave limited evidence after the fact. By the time the investigation begins, the facility may have been cleaned, personnel may have moved to other operations, and the exact conditions surrounding the event cannot be recreated.
Pressure to identify a definitive root cause can then produce weak conclusions such as analyst error or an isolated contamination event without adequate supporting evidence. That creates additional inspection exposure because the CAPA and batch decision are built on an uncertain premise presented as established fact.
A stronger record distinguishes facts from hypotheses and explains the residual uncertainty. Batch impact, related lots, prior signals, process controls, and the adequacy of existing contamination controls still require evaluation even when the precise contamination pathway remains unresolved.
When should a sterility failure trigger investigation beyond the affected batch or test event?
The scope should expand when the evidence suggests that the contamination mechanism could affect other batches, products, equipment, personnel, or periods of operation. The decision should follow the potential extent of the failure mechanism rather than remain confined to the batch in which contamination happened to be detected.
Suppose the investigation identifies a questionable aseptic intervention, compromised equipment condition, recurring environmental signal, cleaning weakness, or personnel practice. The relevant question becomes when that condition began, where else it existed, and what other operations depended on the same control.
This is where investigation timelines matter. Looking only at the failed batch can miss earlier warning signals or subsequent exposure before corrective action was implemented.
Inspection concern increases when the investigation identifies a potentially systemic weakness but the impact assessment remains narrowly batch-specific without explaining why. A defensible scope decision shows how the suspected contamination pathway was traced across potentially affected operations and why the boundaries of the investigation were scientifically justified.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


